Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

Atkins, MB; Jegede, OA; Haas, NB; McDermott, DF; Bilen, MA; Stein, M; Sosman, JA; Alter, R; Plimack, ER; Ornstein, M; Hurwitz, M; Peace, DJ; Signoretti, S; Denize, T; Cimadamore, A; Wu, CJ; Braun, D; Einstein, D; Catalano, PJ; Hammers, H

Atkins, MB (通讯作者)，Georgetown Univ, Med Ctr, Georgetown Lombardi Comprehens Canc Ctr, New Res Bldg Suite 501E,3970 Reservoir Rd NW, Washington, DC 20057 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (25): 2913

Abstract

PURPOSE To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索